Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic - Takeaways - MDSpire

Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic

  • By

  • Jonathan Carmichael

  • Frances Seymour

  • Graham McIlroy

  • Sarrah Tayabali

  • Rosie Amerikanou

  • Sylvia Feyler

  • Rakesh Popat

  • Guy Pratt

  • Christopher Parrish

  • A. John Ashcroft

  • Graham H. Jackson

  • Gordon Cook

  • March 15, 2023

  • 0 min

Share

  • 1

    Multiple myeloma often presents with vague symptoms, leading to frequent emergency diagnoses associated with poorer survival outcomes.

  • 2

    The COVID-19 pandemic caused a significant decline in urgent cancer referrals, impacting timely diagnosis and treatment of multiple myeloma.

  • 3

    Patients with multiple myeloma experienced delays in diagnosis due to altered healthcare pathways during the pandemic, worsening disease burden.

  • 4

    A clinical audit revealed no significant differences in age or gender between pre-COVID and post-COVID cohorts of newly diagnosed myeloma patients.

  • 5

    The pandemic's impact on cancer care will take years to fully understand, particularly regarding delayed diagnoses and patient outcomes.

Original Source(s)

Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic

  • by Jonathan Carmichael, Frances Seymour, Graham McIlroy, Sarrah Tayabali, Rosie Amerikanou, Sylvia Feyler, Rakesh Popat, Guy Pratt, Christopher Parrish, A. John Ashcroft, Graham H. Jackson, Gordon Cook

  • March 15, 2023

Related Content

A propensity score matching study on clinical characteristics and risk factors of herpes zoster in malignant tumor

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Differential expression of immune activation markers in T cells from patients with multiple myeloma